Ketamine enhancement of dexmedetomidine attenuation of methamphetamine-induced agitation in rats
Journal of Pharmacy & Pharmaceutical Sciences · 15.04.2026 · 29
DOI: 10.3389/jpps.2026.16294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 15.04.2026. Verfasst von Madhuri Budamkayala und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Marshall University School of Pharmacy, Huntington, WV, United States. Hauptthemen laut MEDLINE: Ketamine, Methamphetamine, Dexmedetomidine, Naloxone. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methamphetamine (METH)-induced agitation, a major concern in acute METH intoxication, is currently treated with benzodiazepines. Due to current polysubstance use patterns in METH consumption, this treatment may fatally exacerbate respiratory depression produced by opioid adulterants or intentionally co-administered opioids. We previously showed that the α2-agonist dexmedetomidine (DEX), which does not potentiate opioid-induced respiratory depression in clinical practice, can be safely and effectively co-administered with naloxone to attenuate METH-induced agitation following naloxone reversal in METH-fentanyl co-intoxicated rats. While the unique arousability of DEX-induced sedation is clinically useful, the current study tested the safety and efficacy of DEX and adjunctive ketamine (KET) in producing deeper, less arousable sedation when needed (i.e., for severe agitation or to facilitate an intricate procedure). Fifteen minutes after 1 mg/kg METH administration in male rats (simulating treatment of naloxone-unmasked agitation with a delay), low-dose (0.032 mg/kg) DEX ± (56 mg/kg) KET, high-dose (0.18 mg/kg) DEX, or saline was administered. Key measurements included METH-induced locomotor activity (a rat model of agitation), the rat coma scale (a quantification of arousability), and α 2 -agonist class side effects. Both high-dose DEX and DEX-KET almost completely attenuated METH-induced locomotor activity for 90 min after administration, but with the combination the sedation was deeper during the most intense METH-induced stimulation, and the α 2 -agonist side effects were less intense and of shorter duration. These data provide proof-of-concept support for the potential use of DEX-KET in producing deeper sedation in METH-induced agitation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Marshall University School of Pharmacy, Huntington, WV, United States.
- Marshall Toxicology, Marshall Health, Scott Depot, WV, United States.
- Department of Family and Community Health, Marshall University Joan C. Edwards School of Medicine, Huntington, WV, United States.
Zitieren
APA
Budamkayala, M., Yalakala, J., Skeen, M. B., Karuturi, S., McPhillen, C., Bailey, K., Davies, T. H., & Hambuchen, M. D. (2026). Ketamine enhancement of dexmedetomidine attenuation of methamphetamine-induced agitation in rats. Journal of Pharmacy & Pharmaceutical Sciences, 29. https://doi.org/10.3389/jpps.2026.16294
Vancouver
Budamkayala M, Yalakala J, Skeen MB, Karuturi S, McPhillen C, Bailey K, et al. Ketamine enhancement of dexmedetomidine attenuation of methamphetamine-induced agitation in rats. Journal of Pharmacy & Pharmaceutical Sciences. 2026;29. doi:10.3389/jpps.2026.16294
BibTeX
@article{Budamkayala2026,
author = {Budamkayala, Madhuri and Yalakala, Jyostna and Skeen, Madison B and Karuturi, Surya and McPhillen, Chelsey and Bailey, Kristen and Davies, Todd H and Hambuchen, Michael D},
title = {Ketamine enhancement of dexmedetomidine attenuation of methamphetamine-induced agitation in rats},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2026},
volume = {29},
doi = {10.3389/jpps.2026.16294}
}
EUVIMED